Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
glycopegylated erythropoietin
- Development stage
- Discontinued
- Lead developer
- Neose Technologies
- Modality
- Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Subcutaneous, Intravenous
01
Overview
Glycopegylated erythropoietin (NE-180) is a long-acting recombinant erythropoietin (EPO) analog developed using proprietary GlycoPEGylation technology. This technology involves the site-specific, enzymatic attachment of polyethylene glycol (PEG) polymers to the glycan chains of the erythropoietin protein using glycosyltransferase enzymes. By linking PEG to glycans remote from the protein's active site, the drug preserves its biological activity while significantly extending its circulating half-life and improving its pharmacokinetic profile compared to first-generation EPO products. It acts as an agonist of the erythropoietin receptor (EpoR), stimulating the production of red blood cells (erythropoiesis). The drug was primarily investigated for the treatment of anemia associated with chronic kidney disease (CKD) and cancer chemotherapy, but development was halted following the liquidation of its developer, Neose Technologies.
- Other names
- GlycoPEG-EPOPEG-EPO
02
Targets
Erythropoietin Receptor
Beyond the preview
Go deeper on glycopegylated erythropoietin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on glycopegylated erythropoietin.